Guan Hao Biotech acquires Hangzhou Huidisen Group

With the 1,8 billion RMB acquisition, Guan Hao Biotech will become China’s second largest pharmaceutical enterprise and extend ist business into regenerative medicine, cell therapy and other drugs. Huidisen is a leader in cephalosporin production.

China Bio news release, October 24, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year. Accept or Deny